2.02
-0.12(-5.61%)
Currency In USD
| Previous Close | 2.14 |
| Open | 2.08 |
| Day High | 2.14 |
| Day Low | 2 |
| 52-Week High | 10.5 |
| 52-Week Low | 1.88 |
| Volume | 73,259 |
| Average Volume | 51,814 |
| Market Cap | 19.5M |
| PE | -0.55 |
| EPS | -3.67 |
| Moving Average 50 Days | 3.12 |
| Moving Average 200 Days | 5.69 |
| Change | -0.12 |
If you invested $1000 in HOOKIPA Pharma Inc. (HOOK) since IPO date, it would be worth $14.43 as of December 22, 2024 at a share price of $2.02. Whereas If you bought $1000 worth of HOOKIPA Pharma Inc. (HOOK) shares 3 years ago, it would be worth $82.45 as of December 22, 2024 at a share price of $2.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
GlobeNewswire Inc.
Nov 11, 2024 9:05 PM GMT
Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safetyNEW YORK and VIENNA,
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
GlobeNewswire Inc.
Oct 31, 2024 1:17 PM GMT
Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024NEW YORK and VIENNA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK)
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
GlobeNewswire Inc.
Oct 30, 2024 11:30 AM GMT
Study done in collaboration with Memorial Sloan Kettering and led by Dr. Winston Wong, Head and Neck Oncologist and Dr. Alan Ho, Chief of the Head and Neck Oncology Service IIT will evaluate eseba-vec in patients who are HPV16+ after treatment for cu